Nine of the world’s top ten global pharmaceutical companies are located in Ireland.

Why are these companies here?
What is the global distribution of the bodies their drugs treat?
What needs, desires and dysfunctions do these bodies manifest?
What relationships do these bodies have with macro economic and social developments in the early 21st century?

Kennedy Browne will investigate these questions, drawing on a wide range of governmental and multinational data as well as anecdotal evidence collated from the internet. The interrogation will depart from a study of the landscape of so-called ‘blockbuster drugs’ (patented brand name drugs). This examination will include their social and economic biographies, their off-label and out of indication uses, their myriad side effects and unexpected combinations with other substances.

Kennedy Browne is the collaborative practice and identity of Gareth Kennedy and Sarah Browne. Kennedy Browne seeks to address the supposedly eternal narrative of neoliberal capitalism as a fiction, and to do so by generating Other, competing fictions in order to cultivate new economic and political imaginaries of difference. These fictions tend to be developed from existing, marginalised materials from within the plot of global capitalism. The use of readymade material in combination with a collaborative method of scripting ensures that Kennedy Browne’s fictions are networked to a variety of complicated but ‘authentic’ referents rather than tied to a singular author.

Recent solo exhibitions include How Capital Moves, Limerick City Gallery of Art Offsite (2011) and 167 at the Centre Culturel Irlandais, Paris (2010). Group exhibitions include L’Exposition Lunatique, Kadist Foundation, Paris, the Lodz Biennale, Poland, the Cairo Biennale, Egypt (all 2010). In 2009 Kennedy Browne co-represented Ireland at the 53rd Venice Biennale and in 2012 they will develop a new project for the Bern Biennale, Switzerland.

* Half of the world’s top ten blockbuster drugs are manufactured in Ireland. Rated by global sales revenue figures as published in Pharmaceutical Executive Magazine, New York, May 2010.